The AHF-CODE reduced study is a prospective, non-randomized, monocenter study performed in patients with heart failure with reduced ejection fraction admitted for worsening heart failure.
The main objective of the AHF-CODE study is to identify congestion markers (clinical, biological and ultrasound) at the end of hospitalization for acute heart failure that are associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge.
Patients hospitalised for acute heart failure.
Patients with reduced ejection fraction (Ejection Fraction <40%) or (40% ≤ Ejection Fraction < 50)
Patients considered clinically discharging from hospitalisation for acute heart failure.
Age ≥18 years
Comorbidity for which the life expectancy is ≤ 3 months
Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion.
History of lobectomy or pneumonectomy lung surgery
Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
Single group
Clinical examination centered on congestion
Procedure/SurgeryClinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Procedure/SurgeryCardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
Biological: Blood sample retrieved for biological assessment and biobanking
Procedure/SurgeryBlood sample collection will be performed before discharge from hospital
Telephone interview
Procedure/SurgeryTelephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
Kansas City Cardiomyopathy Questionnaire (KCCQ)
BehavioralQuestionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Rate of all-cause death
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 3 months following day hospitalization (with outcome 2 and 3)
Rate of re-hospitalisation for acute heart failure
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 3 months following day hospitalization (with outcome 1 and 3)
Rate of day-hospital or in-home IV diuretics injection for acute HF
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 3 months following day hospitalization (with outcome 1 and 2)
Rate of all-cause death
Rate of re-hospitalisation for acute heart failure
Rate of day-hospital IV diuretics injection for acute HF
Rate of all-cause death
composite endpoint : Rate of all-cause death or hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 8)
Click on the lead sponsor to view all of their trials.
